13G Filing: VenBio Select Advisor and Mirati Therapeutics Inc. (MRTX)

Page 4 of 7 – SEC Filing

Item 1(a). NAME OF ISSUER
Mirati Therapeutics, Inc. (the “Issuer”)
Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
9393 Towne Centre Drive, Suite 200, San Diego, California 92121
Item 2(a). NAME OF PERSON FILING
This statement is filed by: (i) venBio Select Advisor LLC, a Delaware limited liability company (“venBio”), which provides investment advisory and management services and has acquired the securities of the Issuer solely for investment purposes on behalf of venBio Select Fund LLC, a Delaware limited liability company, and certain managed accounts and (ii) Behzad Aghazadeh (“Dr. Aghazadeh,” and together with venBio, the “Reporting Persons”), who serves as the portfolio manager and controlling person of venBio.
The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
The address of the business office of each of the Reporting Persons is 120 West 45th Street, Suite 2802, New York, NY 10036.
Item 2(c). CITIZENSHIP
venBio is a Delaware limited liability company.  Dr. Aghazadeh is a United States citizen.
Item 2(d). TITLE OF CLASS OF SECURITIES
Common Stock, $0.001 par value (the “Common Stock“)
Item 2(e). CUSIP NUMBER
60468T105

Follow Mirati Therapeutics Inc. (NASDAQ:MRTX)